Raf-265

Raf-265

SCHEMBL1562237

Cl.Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

BRAFKDR

The experimentally established mechanism targets of Raf-265. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF known ✓ P15056 17/20 1.00
KDR known ✓ P35968 5/20 1.00
RAF1 P04049 7/20 1.00
LCK P06239 3/20 1.00
FYN P06241 3/20 1.00
PDGFRB P09619 3/20 1.00
KIT P10721 3/20 1.00
FLT1 P17948 3/20 1.00
FLT4 P35916 3/20 1.00
STK25 O00506 1/20 1.00
CIT O14578 1/20 1.00
EPHB6 O15197 1/20 1.00
MAP3K7 O43318 1/20 1.00
RIPK2 O43353 1/20 1.00
PAK3 O75914 1/20 1.00
STK10 O94804 1/20 1.00
MAP4K4 O95819 1/20 1.00
ABL1 P00519 1/20 1.00
CSF1R P07333 1/20 1.00
YES1 P07947 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Raf-265 SCHEMBL686452 1.00 BRAF (1.00) BRAFRAF1KDRLCKFYN
Raf-265 SCHEMBL29368571 1.00 BRAF (1.00) BRAFRAF1KDRLCKFYN
Raf-265 SCHEMBL29355586 1.00 BRAF (1.00) BRAFRAF1KDRLCKFYN
Raf-265 SCHEMBL1562780 0.95 BRAF (0.91) BRAFRAF1KDRLCKFYN
SCHEMBL1435408 0.95 BRAF (1.00) BRAFRAF1KDRLCKFYN
SCHEMBL19661215 0.95 BRAF (0.91) BRAFRAF1KDRLCKFYN
SCHEMBL9976647 0.95 BRAF (0.90) BRAFRAF1KDRLCKFYN
Raf-265 SCHEMBL1561942 0.94 BRAF (0.88) BRAFRAF1KDRLCKFYN
SCHEMBL11996499 0.93 BRAF (0.87) BRAFRAF1KDRLCKFYN
SCHEMBL681128 0.93 BRAF (0.87) BRAFRAF1KDRLCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501785-B2 Salts of benzimidazolyl pyridyl ethers and formulations thereof NOVARTIS AG (CH) 2013-08-06 US disclosed
US-20120308651-A1 SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF NOVARTIS AG 2012-12-06 US disclosed
US-8202998-B2 Salts of benzimidazolyl pyridyl ethers and formulations thereof NOVARTIS AG (CH) 2012-06-19 US disclosed
EP-2059518-B1 SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF NOVARTIS AG (CH) 2011-04-06 EP disclosed
US-20100168060-A1 SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF NOVARTIS AG (CH) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120308651-A1 SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF PIR, BRD8, PHOSPHO1 BRAF 542/4885KDR 2799/4885RAF1 874/4885
US-20100168060-A1 SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF PIR, BRD8, PHOSPHO1 BRAF 542/4885KDR 2799/4885RAF1 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.